赖氨酸素补充剂对糖尿病前期的影响:一项随机对照试验的研究方案
该研究为在斯里兰卡开展的随机双盲安慰剂对照临床试验,计划招募110名糖尿病前期成人,按1:1随机分配接受赖氨酸素片(含赖氨酸、锌和维生素C)每日三次每次两片或安慰剂,干预6个月,主要结局为糖化血红蛋白(HbA1c)较基线的变化。
要点
- 赖氨酸素含赖氨酸、锌和维生素C,假设对糖尿病前期血糖控制有益。
- 随机双盲安慰剂对照设计,110名成人按1:1分组,干预6个月。
- 主要结局为HbA1c较基线变化,设筛查、1月、3月、6月随访。
核心结论
- 据作者所知,这是首批评估赖氨酸素(赖氨酸、维生素C和锌组合)在糖尿病前期中效果的随机对照试验之一。
- 该研究将为未来大规模多中心临床试验提供必要基础。
- 无论结果阳性或阴性,都应能为指导当前和未来糖尿病前期管理政策提供证据上的重大转变。
研究设计与样本
- 研究为随机、双盲、安慰剂对照临床试验,为期6个月。
- 研究已获斯里兰卡科伦坡大学医学院伦理审查委员会批准。
- 计划招募110名糖尿病前期成人,按1:1比例随机分配至试验组和安慰剂组。
- 试验组接受赖氨酸素片每次两片、每日三次,对照组接受相同外观的安慰剂片。
- 研究药物对研究者和受试者均设盲;访视包括筛查(第0次)、1个月(第1次)、3个月(第2次)和6个月(第4次)。
主要发现
- 主要结局定义为以HbA1c测量的血糖控制较基线的变化。
- 数据将使用SPSS v16进行分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetes mellitus is rapidly becoming one of the leading causes of morbidity and mortality worldwide. Preventive measures have become important, especially in the South Asian region and other parts of the world where diabetes is becoming increasingly prevalent. We postulate that a product containing amino acid lysine, micronutrient zinc and vitamin C will have beneficial effects on glycemic control and disease progression in patients with pre-diabetes and we aim to evaluate this hypothesis using a phase II/III randomized double-blind controlled clinical trial design. METHODS/DESIGN: The study will be conducted as a randomized, double-blind, placebo-controlled clinical trial for a period of 6 months. The study has been approved by the Ethics Review Committee of Faculty of Medicine, University of Colombo, Sri Lanka. A total of 110 adults with pre-diabetes will be recruited for the study. They will be randomly assigned to the test and placebo groups on a 1:1 ratio. The test group will receive two tablets of Lysulin™ three times a day and the control group will receive identical placebo tablets. The study drugs will be double blinded to both investigators and subjects. The visits and the evaluations will be done as follows: screening (visit 0), 1 month (visit 1), 3 months (visit 2) and 6 months (visit 4). The primary outcome will be defined as change in glycemic control measured by HbA1c from baseline. Data will be analyzed using SPSS v16. DISCUSSION: To our knowledge this is one of the first randomized controlled trials evaluating the effects of Lysulin™ (a combination of lysine, vitamin C and zinc) in pre-diabetes. This study will provide the necessary groundwork for future large-scale multicentered clinical trials. The result, positive or negative, should provide a step change in the evidence guiding current and future policies regarding management of pre-diabetes. TRIAL REGISTRATION: Sri Lanka Clinical Trials Registry, SLCTR/2018/022 . Registered on 13 July 2018. Study protocol version 2.0 (23 March 2018).
引用
- Ranasinghe P, Jayawardena R, Chandrasena L, et al. Effects of Lysulin™ supplementation on pre-diabetes: study protocol for a randomized controlled trial. Trials. 2019. PMID: 30885259. doi:10.1186/s13063-019-3269-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。